Extravasation
The Product
Mechanism of Action
Efficacy
Tolerability
Administration
SmPC
Presentations
Publications
Summary
References

1/2     

  Prev

Next  



Savene® is indicated for the treatment of anthracycline extravasation


Savene® is the first and only proven and approved antidote to anthracycline extravasation.
   

Only Savene® shows protection against the potentially devastating effects of anthracycline extravasation
   

Savene® was designated as an orphan medicinal product by the EMEA in September 2001 and by the FDA in March 2004
   

Savene® was granted marketing authorisation by the European Commission on 28 July 2006 for the indication 'Treatment of anthracycline extravasation'. The Marketing Authorisation was renewed in July 2011.


Infusion of Savene® should be initiated as soon as possible and within six hours after the accident.
   

Savene® is provided as an easy to use Emergency kit containing 10 vials of 500 mg Savene® Powder and 3 bags of specifically formulated Savene® Diluent for infusion for a complete treatment course of one extravasation

   

Due to the lack of data in the following patient populations treatment with Savene® is not recommended in:

 

- the elderly

 

- children below the age of 18 years 
 

- pregnant women

 

- patients with significant renal or hepatic impairment